Clinical Trial Update: Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluated Meta-Iodobenzylguanidine (123I-mIBG) scintigraphy imaging in patients with heart failure and control subjects without cardiovascular dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Meta-Iodobenzylguanidine (I-123) imaging agent (Iobenguane I-123)

Snippet

Sponsor: GE Healthcare | Conditions: Heart Failure, Congestive | Phase 3 | Status: COMPLETED | Results posted: 2017-05-05